Trial Profile
A Randomized, Multicenter, Open-Label Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Necitumumab (Primary) ; Cisplatin; Gemcitabine
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms SQUIRE
- Sponsors Eli Lilly and Company; ImClone Systems
- 19 Mar 2024 Planned End Date changed from 31 Dec 2023 to 1 Jun 2024.
- 12 Apr 2023 Planned End Date changed from 31 Jul 2023 to 31 Dec 2023.
- 30 Apr 2022 This trial has been completed in Hungary according to European Clinical Trials Database record.